X0201 3/A 2004-03-16 2004-03-10 0 0001130166 XCYTE THERAPIES INC XCYT 0001031836 ARCH VENTURE FUND III L P 8725 W HIGGINS ROAD SUITE 290 CHICAGO IL 60631 0 0 1 0 Series A Convertible Preferred Stock 2004-03-16 Common Stock 28707 D Series B Convertible Preferred Stock 2004-03-16 Common Stock 305785 D Series C Convertible Preferred Stock 2004-03-16 Common Stock 203502 D Series D Convertible Preferred Stock 2004-03-16 Common Stock 240352 D Series E Convertible Preferred Stock 2004-03-16 Common Stock 170045 D Warrants to purchase Series A Convertible Preferred Stock 5.225 2004-03-19 2007-08-31 Series A Convertible Preferred Stock/Common Stock 50237 D Warrants to purchase Common Stock 1.65 2004-03-19 2005-08-08 Common Stock 26918 D Warrants to purchase Common Stock 0.055 2004-03-19 2006-11-12 Common Stock 92580 D 6% Convertible Promissory Note 9.625 2004-03-16 2004-04-30 Common Stock 61363 D Series A Convertible Preferred Stock 2004-03-16 Common Stock 114832 I Footnote Series B Convertible Preferred Stock 2004-03-16 Common Stock 66115 I Footnote 6% Convertible Promissory Note 9.625 2004-03-16 2004-04-30 Common Stock 293477 I Footnote Series F Convertible Preferred Stock 2004-03-16 Common Stock 163473 I Footnote Warrants to purchase Common Stock 0.055 2004-03-19 2007-02-04 Common Stock 89002 I Footnote These securities are preferred stock of Xcyte Therapies, Inc. and do not have an expiration date. Each share of its preferred stock will convert automatically into one share of common stock upon closing of the initial public offering. Represents securities held by ARCH Venture Fund II, L.P., an affiliated entity of the Reporting Person. ARCH Venture Fund II, L.P. holds 114,832 shares of common stock upon conversion of preferred stock. Represents securities held by ARCH Venture Fund II, L.P., an affiliated entity of the Reporting Person. ARCH Venture Fund II, L.P. holds 66,115 shares of common stock upon conversion of preferred stock. Represents a warrant to purchase 50,237 shares of preferred stock which would convert to common stock upon the close of initial public offering. Warrant is exercisable at the earlier of a close of an initial public offering or its expiration date. Represents a warrant to purchase 26,918 shares of common stock. Warrant is exercisable at the earlier of a close of an initial public offering or its expiration date. Represents a warrant to purchase 92,580 shares of common stock. Warrant is exercisable at the earlier of a close of an initial public offering or its expiration date. Represents promissory notes at 6%. Interest and principal convertible into shares of common stock at the close of the initial public offering at $9.625 per share. In addition, ARCH Venture Fund III, L.P. holds 9,402 shares of common stock upon conversion of warrant; however, these warrants are null and void if the company completes its initial public offering, and as such are not reported. Represents promissory notes at 6% held by ARCH Venture Fund V, L.P. (AVFV), ARCH V Entrepreneurs Fund, L.P. (AVEF) and Healthcare Focus Fund, L.P. (HFF), each of which is an affiliated entity of the Reporting Person. Interest and principal convertible into shares of common stock at the close of the initial public offering at $9.625 per share. AVFV holds 212,009 shares of common stock upon conversion of promissory notes, AVEF holds 1,428 shares of common stock upon conversion of promissory notes, and HFF holds 80,039 shares of common stock upon conversion of promissory notes. In addition, AVFV, HFF and AVEF each hold a warrant to purchase shares of common stock; however, these warrants are null and void if the company completes its initial public offering, and as such are not reported. Represents securities held by Healthcare Focus Fund, L.P., an affiliated entity of the Reporting Person. Warrant is exercisable at the earlier of a close of an initial public offering or its expiration date. Represents 163,473 shares of common stock upon conversion of preferred stock held by Healthcare Focus Fund, L.P., an affiliated entity of the Reporting Person. Share amounts reflect a 5.5 to 1 reverse stock split effective immediately prior to the closing of the initial public offering. ARCH Venture Fund III, L.P., By: ARCH Venture Partners, LLC, Its: General Partner, By: Keith Crandell, Managing Partner, By:/s/Keith Crandell 2004-03-17